475160-83-9

Basic information

• Product Name: FMOC-4-AMINOBENZYLALCOHOL
• Synonyms: FMOC-4-AMINOBENZYLALCOHOL;(9H-Fluoren-9-yl)methyl (4-(hydroxymethyl)phenyl)carbamate
• CAS NO: 475160-83-9
• Molecular Formula: C₂₂H₁₉NO₃
• Molecular Weight: 345.39
• Mol File: 475160-83-9.mol

Chemical Properties

• Boiling Point: 520.4±38.0 °C(Predicted)
• Appearance: /
• Density: 1.293±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.05±0.70(Predicted)
• CAS DataBase Reference: FMOC-4-AMINOBENZYLALCOHOL(CAS DataBase Reference)
• NIST Chemistry Reference: FMOC-4-AMINOBENZYLALCOHOL(475160-83-9)
• EPA Substance Registry System: FMOC-4-AMINOBENZYLALCOHOL(475160-83-9)

Safety Data

• Hazardous Substances Data: 475160-83-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
FMOC-4-aminobenzylalcohol is employed as a protecting group for amines, playing a crucial role in organic synthesis. Its ability to be easily removed under mildly acidic conditions facilitates the isolation of the free amine, which is vital for the synthesis of various complex organic molecules.
Used in Pharmaceutical Production:
In the pharmaceutical industry, FMOC-4-aminobenzylalcohol is utilized in the production of pharmaceuticals and biologically active compounds. Its protective properties for amines are instrumental in the synthesis of drugs that require amine groups, ensuring the integrity of these groups during the manufacturing process.
Used in Biological Compounds Synthesis:
FMOC-4-aminobenzylalcohol also finds application in the synthesis of biologically active compounds. Its role in protecting amine groups is essential for the successful synthesis of bioactive molecules, which often involve intricate chemical structures that require the preservation of specific functional groups.

Upstream product

• 623-04-1 4-aminobenzenemethanol 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 

Downstream Products

• 914094-76-1 (4-chloromethyl-phenyl)-carbamic acid 9H-fluoren-9-ylmethyl ester 

Relevant articles and documents

Near-Infrared Fluorescent Molecular Probe for Sensitive Imaging of Keloid

Early detection of skin diseases is imperative for their effective treatment. However, fluorescence molecular probes that allow this are rare. The first activatable near-infrared (NIR) fluorescent molecular probe is reported for sensitive imaging of keloi

Beyond Basicity: Discovery of Nonbasic DENV-2 Protease Inhibitors with Potent Activity in Cell Culture

The viral serine protease NS2B-NS3 is one of the promising targets for drug discovery against dengue virus and other flaviviruses. The molecular recognition preferences of the protease favor basic, positively charged moieties as substrates and inhibitors, which leads to pharmacokinetic liabilities and off-target interactions with host proteases such as thrombin. We here present the results of efforts that were aimed specifically at the discovery and development of noncharged, small-molecular inhibitors of the flaviviral proteases. A key factor in the discovery of these compounds was a cellular reporter gene assay for the dengue protease, the DENV2proHeLa system. Extensive structure-activity relationship explorations resulted in novel benzamide derivatives with submicromolar activities in viral replication assays (EC50 0.24 μM), selectivity against off-target proteases, and negligible cytotoxicity. This structural class has increased drug-likeness compared to most of the previously published active-site-directed flaviviral protease inhibitors and includes promising candidates for further preclinical development.

DIRECTED CONJUGATION TECHNOLOGIES

Among other things, the present disclosure provides technologies for site-directed conjugation of various moieties of interest to target agents. In some embodiments, the present disclosure utilizes target binding moieties to provide high conjugation efficiency and selectivity. In some embodiments, provided technologies are useful for preparing antibody conjugates.

NEAR INFRA-RED MOLECULAR PROBES FOR USE IN DIAGNOSIS OF FIBROTIC CONDITIONS AND SCREENING OF ANTI-FIBROTIC DRUGS

We disclose a compound of formula I: [X]n-[Y]m-Z where X represents a fluorophore group covalently linked to the rest of the molecule by way of an oxygen atom or an NH group; Y is a self-immolative linking group; Z represents an N-bl

Synthesis and biological characterization of protease-activated prodrugs of doxazolidine

Doxazolidine (doxaz) is a new anthracycline anticancer agent. While structurally similar to doxorubicin (dox), doxaz acts via a distinct mechanism to selectively enhance anticancer activity over cardiotoxicity, the most significant clinical impediment to successful anthracycline treatment. Here, we describe the synthesis and characterization of a prodrug platform designed for doxaz release mediated by secreted proteolytic activity, a common association with invasiveness and poor prognosis in cancer patients. GaFK-Doxaz is hydrolyzable by the proteases plasmin and cathepsin B, both strongly linked with cancer progression, as well as trypsin. We demonstrate that activation of GaFK-Doxaz releases highly potent doxaz that powerfully inhibits the growth of a wide variety of cancer cells (average IC50 of 8 nM). GaFK-Doxaz is stable in human plasma and is poorly membrane permeable, thereby limiting activation to locally secreted proteolytic activity and reducing the likelihood of severe side effects.

METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF

The invention provides therapeutically effective compounds for the prevention and treatment of cancer and pharmaceutical compositions containing these compounds as well as methods of using and administering these compounds. The invention also includes methods of activating a prodrug of these therapeutically effective compounds by the administration of a peptide-directed targeting construct that delivers a prodrug-activating enzyme to a target activation site.

Synthesis of rigid photoswitchable hemithioindigo ω-amino acids

The synthesis of novel N-Boc- and N-Fmoc protected hemithioindigo-based ω-amino acids is described. An approach to modulate the thermal stability of a hemithioindigo subunit is presented. Placing the amino-group in the stilbene part from the para- to meta

4-PHENYL-5-OXO-1,4,5,6,7,8-HEXAHYDROQUINOLINE DERIVATIVES THE TREATMENT OF INFERTILITY

The present invention relates to 4-phenyl-5-oxo-l,4)5,6,7,8-hexahydroquinoline derivatives according to Formula I, Formula I or a pharmaceutically acceptable salt thereof, wherein R1 is (l-6C)alkyl, (2-6C)alkenyl or (2-6C)aDcynyl; R2, R3 are independently halogen, (l-4C)allcyl, (2-4C)alkenyl, (2-4C)- alkynyl, (1 -4C)aBcoxy, (3-4C)alkenyloxy or (3-4C)alkynyloxy; R4 is phenyl or (2-5C)- heteroaryl, both substituted with R7 and optionally substituted on the (hetero)aromatic ring with one or more substituents selected from hydroxy, amino, halogen, nitro, trifluoromethyl, cyano, (l-4C)alkyl, (l-4C)alkoxy , (l-4C)alkylthio and (di)(l-4C)- alkylamino. The invention also relates to pharmaceutical compositions comprising said derivatives, as well as to the use of these 4-phenyl-5-oxo-l, 4,5,6, 7,8-hexahydro- quinoline derivatives in therapy, more specifically for the treatment of infertility

Dioxanes and uses thereof

In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1, R2, R3, n, X and Y are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The present invention further provides compounds capable of inhibiting histone deacetylatase activity and methods for treating disorders regulated by histone deacetylase activity (e.g., cancer and protozoal infections) comprising administering a therapeutically effective amount of a compound of formula (I) to a subject in need thereof. The present invention additionally provides methods for modulating the glucose-sensitive subset of genes downstream of Ure2p. The present invention also provides methods for preparing compounds of the invention.

Dioxanes and uses thereof

In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1, R2, R3, n, X and Y are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The present invention further provides compounds capable of inhibiting histone deacetylatase activity and methods for treating disorders regulated by histone deacetylase activity (e.g., cancer and protozoal infections) comprising administering a therapeutically effective amount of a compound of formula (1) to a subject in need thereof. The present invention additionally provides methods for modulating the glucose-sensitive subset of genes downstream of Ure2p.